AI-generated analysis. Always verify with the original filing.
Bicara Therapeutics Inc. issued a press release on February 19, 2026, announcing that Ficerafusp Alfa 2000mg Q2W demonstrates deep, durable responses. The filing includes Exhibit 99.1, the press release, under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits.
Event Type
Disclosure
Voluntary
Variant
8-K
Other Events. On February 19, 2026, Bicara Therapeutics Inc. issued a press release entitled “Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses in
Financial Statements and Exhibits (d) The following exhibits are being filed herewith: Exhibit No. Description 99.1 Press Release, dated February 19, 2026. 104